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Inflammatory breast cancer (IBC) is an uncommon disease, occur-
ring in about 2–4% of all breast cancer (Jaiyesimi et al, 1992). It is
generally defined as a clinical entity, corresponding to the T4d
stage of the 1988 UICC classification.
Despite its low frequency, IBC remains a challenge for oncolo-
gists. When treated with surgery or radiotherapy alone, or both,
5-year survival did not exceed 15% (Swain and Lippman, 1989).
Generalization of neoadjuvant chemotherapy has largely improved
treatment of IBC, but prognosis is still very poor, with 5-year
survival rates between 30 and 50% (Rouëssé et al, 1986; Bauer et
al, 1995), and there is no current consensus on the ‘best’ induction
chemotherapy regimen. Response to initial chemotherapy has
been described as predictive of outcome, with progression-free
and overall survival significantly higher for responding patients
than for non-responding patients (Chevallier et al, 1987; Palangie
et al, 1994). Achievement of complete pathological response
seems a particularly important prognostic factor (Feldman et al,
1986; Noguchi et al, 1988; Maloisel et al, 1990; Armstrong et al,
1993; Sataloff et al, 1995). We can therefore speculate that
improving efficacy of first-line chemotherapy could be one
method of improving IBC prognosis.
Based on in vitro and animal models (Frei and Canellos, 1980;
Griswold et al, 1987), showing dose–response relationship for
several anticancer drugs, especially alkylating agents, and retro-
spective studies evaluating the impact of dose intensity in breast
cancer (Hryniuk and Bush, 1984), a number of pilot studies have
tested the impact of dose escalation, including high-dose
chemotherapy with stem cell transplantation in breast cancer
(Antman and Gale, 1988; Peters et al, 1993). Large studies have
been done in metastatic or non-metastatic poor prognosis breast
cancer, in which high-dose chemotherapy was generally
performed after induction by conventional chemotherapy, and in
selected patients with responding disease in metastatic situation.
This strategy allows delivery of very high-dose chemotherapy,
generally alkylating agents, in a single course using the concept of
dose effect.
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Summary Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of
inflammatory breast cancer (IBC) is still poor. In this work, we evaluate response and toxicity of high-dose sequential chemotherapy with
repeated blood stem cell (BSC) transplantation administered as initial treatment in 100 women with non-metastatic IBC. Ninety-five patients
(five patients were evaluated as non-eligible) of median age 46 years (range 26–56) received four cycles of chemotherapy associating:
cyclophosphamide (C) 6 g m–2 – doxorubicin (D) 75 mg m–2 cycle 1, C: 3 g m–2 – D: 75 mg m–2 cycle 2, C: 3 g m–2 – D: 75 mg m–2 – 5 FU
2500 mg m–2 cycle 3 and 4. BSC were collected after cycle 1 or 2 and reinfused after cycle 3 and 4. rG-CSF was administered after the four
cycles. Mastectomy and radiotherapy were planned after chemotherapy completion. Pathological response was considered as the first end
point of this trial. A total of 366 cycles of chemotherapy were administered. Eighty-seven patients completed the four cycles and relative dose
intensity was respectively 0.97 (range 0.4–1.04) and 0.96 (range 0.25–1.05) for C and D. Main toxicity was haematological with febrile
neutropenia ranging from 26% to 51% of cycles; one death occurred during aplasia. Clinical response rate was 90% ± 6%. Eighty-six patients
underwent mastectomy in a median of 3.5 months (range 3–9) after the first cycle of chemotherapy; pathological complete response rate in
breast was 32% ± 10%. All patients were eligible to receive additional radiotherapy. High-dose chemotherapy with repeated BSC
transplantation is feasible with acceptable toxicity in IBC. Pathological response rate is encouraging but has to be confirmed by final outcome.
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Correspondence to: P ViensAnother possibility of intensifing chemotherapy is to increase
doses along multiple cycle, using the concept of dose intensity in
first-line treatment. The use of haematopoietic growth factors
and/or peripheral stem cells allows regimen to be designed (Basser
et al, 1995; Swain et al, 1996; Shipp et al, 1995; Stoppa et al,
1997; Viens et al, 1997) in which dose and dose intensity are
significantly increased. These can then be given safely, as out
patient first-line treatment with the objective of improving
chemotherapy response and disease prognosis in the whole patient
population.
Based on those considerations, the High Dose Chemotherapy
for Breast Cancer Study Group (PEGASE) of the French
Federation of Anticancer Centers initiated such a study (PEGASE
02) aimed at evaluating: toxicity and feasibility of high-dose
sequential chemotherapy with rG-CSF (filgrastim) and stem
cell support in inflammatory breast cancer, response to this
chemotherapy with emphasis on pathological response and,
secondary, impact on disease-free survival and survival. We
report here toxicity and response rate.
MATERIALS AND METHODS
Eligibility
One hundred consecutive women with primary inflammatory
breast cancer were included in this study. Inflammatory breast
cancer was defined as follows: histologically documented adeno-
carcinoma of the breast with inflammatory signs (erythema, ‘peau
d’orange’ appearance and increase in local temperature) which
involved ³ one-third of the breast (T4d of the 1988 International
Union Against Cancer [UICC] classification). Absence of dermal
lymphatic carcinomatosis was not a criterion for exclusion.
Other inclusion criteria were: age between 18 and 60 years,
WHO performance status ≤ 2, no previous history of malignancy,
normal cardiac function assessed by a normal ECG and normal left
ventricular ejection fraction estimated by echocardiography or
radionuclide cardiac scan, polynuclear neutrophil count greater
than 1.5 ´ 109 l–1, platelet count superior to 100 ´ 109 l–1, total
bilirubin, serum creatinin, ASAT and ALAT inferior to 1.25 times
the upper limit of normal range.
Patients with locally advanced breast cancer (other T4 of the
1988 UICC classification), secondary inflammatory breast cancer
or metastatic breast cancer (including supraclavicular lymph node
involvement) were excluded from the study. The baseline evalua-
tion included physical examination, bilateral mammography and
breast echography, chest X-ray, radionuclide bone scan, liver
echography, bone marrow aspiration (for further comparison with
leukapheresis product) and, if possible, two bone marrow biopsies,
standard biological tests and CA 15-3 assay.
Other exclusion criteria were the presence of another conco-
mitant serious illness and an uncontrolled ongoing infection at
entry into the study. In accordance with French law, the study was
approved by the ethical committee (CCPPRB) of the University of
Toulouse and patients had to provide written informed consent
before entering the study.
Treatment plan
Treatment was a combined modality approach including high-dose
sequential chemotherapy with rG-CSF (filgrastim) and peripheral
blood stem cell support as induction chemotherapy.
Initial local treatment
Initial surgery was performed to acquire pathological documenta-
tion of invasive breast cancer and varied according to each centre
policy, from needle biopsy to tumour biopsy with skin biopsy
and/or axillary dissection.
Chemotherapy 
Four cycles of chemotherapy were administered every 21 days.
Cycle one consisted of cyclophosphamide 6 g m–2 and doxorubicin
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Figure 1 Pegase 02 regimen. C = Cyclophosphamide: 3 g m–2 day–1. Dox = Doxorubicin: 75 mg m–2. 5-FU = Fluorouracil: 500 mg m–2 day–1 continuous
infusion. BSC: Blood stem cells. D: day.75 mg m–2, cycle 2 of cyclophosphamide 3 g m–2 and doxorubicin
75 mg m–2, cycle 3 and 4 of cyclophosphamide 3 g m–2 doxorubin
75 mg m–2 and 5-fluorouracil (5-FU) 2500 mg m–2. Cyclo-
phosphamide was administered as a 1-h intravenous (i.v.) infusion,
dose was divided by two and administered for 2 consecutive days
in cycle 1, doxorubicin was given as a 15-min i.v. infusion and
5-FU as a 5-day continuous i.v. infusion. Uromitexan was given in
the same dosage as cyclophosphamide, as a 24-h continuous
i.v. infusion, starting 1 h before cyclophosphamide. Anti-emetic
prophylaxis was assured by anti-HT3 serotonin receptors and
corticoid. There was no guideline for salvage treatment.
Semi-saline hyperhydradation (3 l m–2 24 h G 5% with sodium
chloride 4.5 g l–1 and potassium chloride 1.5 g l–1) was started 4 h
before cyclophosphamide and stopped 20 h after the end of
cyclophosphamide infusion. Uroprotection was assured by uromi-
texan only at cycle 1. Chemotherapy was administered if absolute
neutrophil count (ANC) was ³ 1.5 ´ 109 l–1 and platelet count
³ 100  ´ 109 l–1. No dose reduction was planned. If patient’s
neutrophil and platelet count did not meet these criteria on day 21,
chemotherapy was delayed until adequate count recovery.
Exclusion of patients from the study because of absence of haema-
tological recovery was left to the decision of each investigator.
For doxorubicin and cyclophosphamide, dose intensity was
calculated as total chemotherapy administered, divided by body
surface area and delay (in weeks) between day 1 of cycle 1 and 3
weeks after day 1 of cycle 4 (or 3 weeks after the theoretical day 1
of cycle 4 for patients who stopped treatment). Relative dose inten-
sity (RDI) was the result of dose intensity divided by theoretical
dose intensity.
rG-GSF, stem cell collection and reinfusion
rG-CSF (filgrastim) was administered at a daily dosage of
5 mg kg–1 (maximum 300 mg kg–1 per day) at each cycle of treat-
ment. Administration started at day 4 of cycle 1 and 2 and day 7
(day of stem cell reinfusion) of cycle 3 and 4. rG-CSF was stopped
the day before last apheresis or when ANC reached 0.5 ´ 109 l–1 on
3 consecutive days for cycles without apheresis.
Apheresis were performed after the first cycle of chemotherapy
and/or after the second, depending on the possibilities of each
centre. Generally, the procedure was started when the absolute
number of CD34+ cells in the peripheral blood rose to 20 ml–1.
Apheresis were stopped when collected CD34+ cells exceeded
4 ´ 106 kg–1. Cells were divided into two bags at least, to allow
reinfusion of a minimum of 2 ´ 106 l–1 CD34+ cells kg–1 after cycle
3 and cycle 4, after storage in liquid nitrogen.
No attempt was made to purge haematopoietic stem cells of
possible tumoural contamination. Haematopoietic stem cells were
reinfused on day 7 of cycle 3 and 4, at least 20 h after the end of
chemotherapy.
Further anticancer therapy
Mastectomy was performed after induction chemotherapy for non-
progressive patients. Locoregional treatment was completed by
radiotherapy, according to procedures in each centre. Finally,
patients who were menopausal at diagnosis and with positive
oestrogen and/or progesterone receptors received Tamoxifene
20 mg day–1 for 3 years.
Supportive care
Patients were discharged from hospital after chemotherapy.
According to policy in each institution, blood stem cell collection
and reinfusion were performed in a conventional hospital unit or in
an out patient clinic. When patients became febrile (> 38°C), they
were hospitalized to receive i.v. antibiotics. Red blood cells were
transfused when haemoglobin was ≤ 8g  d l –1 or for anaemia
symptoms and platelets were transfused when platelet count was
< 20 ´ 109 l–1 or for haemorrhagic symptoms. All blood products,
except blood stem cells, were irradiated at 25 Gy.
Toxicity evaluation
Once per course (D1) physical examination was carried out and
Karnofsky index, vital signs, electrocardiogram, complete blood
count (CBC) and differential, liver function and creatinin were
assessed. During the treatment period, CBC and differential were
obtained 3 times a week. At the end of chemotherapy, pretreatment
evaluation was repeated, except radionuclide bone scan, marrow
aspiration and bone marrow biopsies. Echocardiography or
radionuclide cardiac scan was performed at the end of chemo-
therapy and after radiotherapy. Toxicities were assessed according
to WHO criteria.
Response evaluation
Clinical
Clinical evaluation was performed on day 1 of each cycle of
chemotherapy and prior to local treatment. Complete clinical
response was defined as clinically complete disappearance of
breast inflammation as well as the underlying breast tumour mass.
Partial response was at least a 50% decrease in tumour diameter
with disappearance of inflammation.
Pathological evaluation
Two independent pathologists performed pathological evaluation
using a blind study technique. Pretreatment samples consisted of
cytology, incisional biopsy or tumourectomy specimens, and,
for some patients, node specimens. Microscopic inspection of
pretreatment specimens allowed tumour typing according to WHO
classification. Several histological parameters were evaluated.
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Table 1 Tumour characteristics
Extent of inflammatory signs
Limited 61%
Diffuse 39%
N
N0 20.2%
N1 58.5%
N2 21.3%
Pathological classification
Ductal 80.2%
Lobular 5.5%
Other 14.3%
SBR grade
I2 %
II 30.8%
III 58.2%
Non-evaluable 9%
Oestrogen/progesterone receptors
+/+ 17%
+/– or –/+ 18%
–/– 42%
Unknown 23%Hormonal receptors were evaluated using immunohistochemistry
or biochemical assay.
Mastectomy specimens were thoroughly examined, with
sections taken from each quadrant, from the nipple areolar
complex and areas suspected of having tumour involvement. A
minimum of 20 samples was done. Three components were
systematically evaluated: intraductal, invasive carcinoma and
vascular invasion. Response in the breast was defined as described
by Chevallier et al (1995):
• Grade 1: disappearance of all tumour both on macroscopic and
microscopic examination
• Grade 2: presence of in situ carcinoma of the breast with no
invasive tumour
• Grade 3: presence of invasive carcinoma with stromal alter-
ations such as sclerosis or fibrosis
• Grade 4: no or few alterations in tumoural appearance.
Lymph nodes were evaluated separately when available after
chemotherapy and classified in two categories: involved or not
involved.
Statistical analysis
No interim analysis on efficacy was performed. However, it was
planned to stop the study if toxic death rate was too high. To keep
toxic death rate under 3% with a 5% a risk, only up to four toxic
deaths among the first 30 patients were accepted (Fleming, 1982).
Medians are presented with their range and response rate with
95% confidence interval. Percentage differentials were tested by
application of the c2 test. When a patient stopped her treatment,
she was analysed for received cycle toxicity, dose intensity and
pathological response if mastectomy was performed before begin-
ning another antineoplasic treatment and for follow-up.
Survival and relapse-free survival were estimated using the
Kaplan–Meier method (Kaplan et al, 1971). Relapse-free survival
was defined as the time elapsed between date of diagnosis and date
of first relapse, wherever this relapse might be. Overall survival
was the period between time of diagnosis and time of last status
report, whether the patient was alive or dead, whatever the cause
of death.
RESULTS
Patients
Between December 1994 and September 1996, 100 patients from
17 participating centres entered the study. Five patients were with-
drawn from the study: four had metastatic inflammatory breast
cancer at diagnosis (positive radionuclide bone scan: two, contra-
lateral or supraclavicular lymph nodes: two) and were not eligible
and one received another chemotherapy regimen before the first
cycle. Finally, 95 patients were valid for analysis.
Median age of patients was 46 years (range 26–59), 83.2% were
premenopausal at time of diagnosis. Initial characteristics of
tumours are summarized in Table 1. Axillary dissection was
initially performed in only 17 patients. Median number of
involved nodes for these patients was 8 (range 0–23), with eight
patients having ten or more involved nodes. Dermal lymphatic
carcinomatosis was found in 43% of patients who had a skin
biopsy.
Stem cell collection and infusion
Ninety-seven per cent of patients had successful collection of
CD34+ cells after cycle 1 and/or cycle 2, and 93% of all patients
after 1 single set of apheresis. Median number of collected
CD34+ cells was 14.75 ´ 106 kg–1 (range 2.3 to > 100), and a
median of 6.05 ´ 106 kg–1 (range 1.2 to >100) and 8.5 ´ 106 kg–1
(range 1.2–59.1) CD34+ cells were respectively reinfused after
cycle 3 and cycle 4.
Toxicity
Non-haematologic toxicity
Grade 3 or 4 vomiting occurred in 14% of cycles, grade 3 or 4
mucositis in 10% of cycles (4% in cycles 1 and 2, 15% in cycle 3
and 4, P < 0.01). Grade 3 hepatic toxicity was seen in one single
patient in cycle 1 and in another patient in cycle 3. No other grade 3
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Table 2 Neutropenia and febrile neutropenia
Cycle 1 Cycle 2 Cycle 3 Cycle 4
ANC <0.1 ´ 109 l–1
Frequency 64% 41%a 48% 56%
Median duration in days (range) 4 (1–16) 3 (1–8) 5 (1–10) 4 (1–10)
ANC <0.5 ´ 109 l–1
Frequency 79% 75% 78% 79%
Median duration in days (range) 5 (1–16) 4 (1–10) 5 (1–10) 5 (1–10)
Incidence of febrile neutropenia 48% 26%b 48% 51%
ANC, absolute neutrophil count. aP < 0.05; bP < 0.01.
Table 3 Thrombopenia and transfusions
Cycle 1 Cycle 2 Cycle 3 Cycle 4
Plts < 20 ´ 109 l–1
Frequency 41% 26%a 44% 46%
Median duration in days (range) 2 (1–15) 1 (1–27) 2 (1–11) 2 (1–12)
Plts < 50 ´ 109 l–1
Frequency 63% 56% 70% 69%
Median duration in days (range) 4 (1–15) 3 (1–33) 5 (1–27) 5 (1–14)
Incidence of plt transfusions 43% 29%b 53% 56%
Median no. of transfusions (range) 1 (1–6) 1 (1–6) 2 (1–5) 1 (1–4)
Incidence of RBC transfusions 37% 38% 66% 83%
Median no. of transfusions (range) 1 (1–6) 1 (1–6) 2 (1–8) 1 (1–4)
Plts, platelets. aP < 0.05; bP < 0.01.
Table 4 Response
Number of Percentage of
evaluable patients responders
Objective clinical response 94 90% ± 6%
Pathological response in breast 87 GR I and II: 32% ± 10%
GR III and IV: 68% ± 10%
GR I = Disappearance of tumour both on macroscopic and microscopic
examination. GR II = Presence of in situ carcinoma of the breast, with no
invasive tumour. GR III = Presence of invasive carcinoma with stromal
alterations such as sclerosis or fibrosis. GR IV = No or few alterations of
tumoural appearance.or 4 toxicities were seen during the study. Monitoring of left ventric-
ular ejection fraction showed no clinically significant diminution.
Haematologic toxicities
Neutropenia and rehospitalization
One patient died from the procedure. She was readmitted for
febrile neutropenia after cycle 1 and died from septic shock with
multi-organ failure. Grade 4 neutropenia occurred in between
75% and 79% of each cycle. Duration of neutropenia inferior
to 0.5 ´ 109 l–1 lasted a median of 5 days per cycle. Febrile
neutropenia was the most frequent reason for rehospitalization
(85% of all rehospitalizations). Overall, there was no cumulative
increase in frequency and duration of neutropenia and complica-
tions over the four cycles. However, cycle 2 was overall signifi-
cantly associated with less toxicity (Table 2). Emergency
readmission was necessary in 51% of the 366 administered cycles.
The median duration of rehospitalization was: 6.5 days (range
1–16), 5 days (range 1–29), 8 days (range 1–19) 6 days (range
2–16) for each cycle.
Thrombopenia and transfusion (Table 3)
Thrombopenia of less than 20 ´ 109 l–1 occurred in 26–46% of
cycles. Duration of thrombopenia inferior to 20 ´ 109 l–1 was a
median 2 days per cycle, with the same duration after each cycle.
Platelets transfusion was needed in an average of 29–56% of
cycles with administration of a median of one transfusion per
cycle.
Chemotherapy delivery
A total of 366 cycles of chemotherapy were administered in 95
evaluable patients. Ninety-three patients received the 2nd cycle, 91
the 3rd cycle and 87 the 4th. Except for the patient who died after
cycle 1, the main reason for stopping chemotherapy was prolonged
haematological toxicity.
Cycle 2 was administered in a median of 21 days (range 18–37)
after cycle 1, cycle 3 in a median of 21 days (range 19–35) after
cycle 2 and cycle 4 in a median of 21 days (range 20–43) after
cycle 3. Cycles 2, 3 and 4 were respectively delayed more than
1 week for four, nine and 11 patients.
Median received dose intensity for cyclophosphamide and
doxorubicin was 1211 mg m–2 week–1 (range 50–1305) and
24 mg m–2 week–1 (range 6–26) with respective relative dose
intensity of 0.97 (range 0.40–1.04) and 0.96 (range 0.25–1.05).
Anti-tumoural response (Table 4)
Clinical response
Out of 94 evaluable patients, one did not have a clinical response
after four cycles of chemotherapy (persistence of inflammatory
signs). All 93 other patients had good clinical response to
chemotherapy with complete disappearance of tumoural signs
(clinical complete response) in 75 (80%). After the 1st cycle of
chemotherapy, inflammatory signs disappeared in 34 patients
(41%).
Pathological response
One patient, with persistence of inflammatory signs, did not
undergo mastectomy and was evaluated as a pathological failure.
For eight other patients with clinical complete response, mastec-
tomy was not performed at the patients’ request. Conservative
treatment was given to these patients. These eight patients were
not evaluated for pathological response. Finally, 86 patients under-
went mastectomy, which was performed in a median of 3.5 months
(range 3–9) after the first cycle of chemotherapy: 28 patients expe-
rienced complete disappearance of tumour cells (grade I) or only
persistence of an intraductal component (grade II) (32 ± 10% of
grade I or II pathological response). In 24 other patients (28 ± 9%),
major changes in histology were found, such as tumour cell
necrosis and stromal alteration showing partial efficacy of
chemotherapy (grade III). However, an invasive component was
persistent in these patients. Finally, in 34 patients (39 ± 10%),
despite good clinical response, no evidence of pathological
response to chemotherapy (grade IV) was seen.
Objective evaluation of response rate in breast and lymph nodes
was difficult to assess since several patients had pathological
complete response in the breast, but had undergone previous axil-
lary dissection. Among the 69 patients who underwent axillary
dissection after chemotherapy, 18 (26 ± 10%) had negative lymph
node.
As clinical complete response was present in 80% of patients, it
was not possible to make any correlation between clinical and
pathological complete response.
Survival 
With a 3-year median follow-up, 29 patients died and 66 are alive.
The estimated 3-year survival is 70% (95% confidence interval
(CI) 60–79%) and the median survival is not reached. Fifty-two
relapses occurred (43 distant and nine local) with a 3-year relapse-
free survival of 44% (95% CI 33–54%).
DISCUSSION
This study was initially designed to evaluate feasibility of high-
dose sequential chemotherapy with rG-CSF and blood stem cell
transplantation in inflammatory breast cancer, to test its impact on
response rate and possibly outcome. As response, and particularly
pathological response (Feldman et al, 1986; Noguchi et al, 1988;
Maloisel et al, 1990; Armstrong et al, 1993; Palangie et al, 1994;
Sataloff et al, 1995), have been described as main prognostic
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Figure 2 Survival (OS) and relapse-free survival (RFS).factors in inflammatory breast cancer, pathological response rate
was considered as an acceptable early end point to test efficacy of
this new chemotherapy regimen.
Acute toxicity related to chemotherapy consisted of mainly
severe but reversible pancytopenia, occurring in all four cycles of
chemotherapy. The second cycle of chemotherapy was less toxic,
leading to fewer cases of severe neutropenia, febrile neutropenia,
thrombopenia and platelet transfusion. This difference was
expected, since cycle 2 differed from cycle 1 in cyclophosphamide
dose (3 g m–2 vs 6 g m–2) and from cycles 3 and 4 by absence of
5-FU.
The relatively short duration of neutropenia is probably related
to use of rG-CSF. One can question the utility of peripheral blood
stem cells in this study, in which there was no myeloablative
chemotherapy. However, it can be noted that the incidence of
severe neutropenia, thrombopenia and febrile neutropenia did not
increase from cycle 1 to cycle 4. In previously published studies of
high-dose doxorubicin-cyclophosphamide regimen with rG-CSF
but without stem cell transplantation (Shipp et al, 1995; Swain
et al, 1996), thrombocytopenia is generally the dose-limiting toxi-
city, this appears to be cumulative and increases significantly
between the first and last cycle (Shipp et al, 1995). These toxicities
occur in the same range of doses as those used in our study:
cyclophosphamide 2000 mg m–2; doxorubicin 40 mg m–2 every
2 weeks (Swain et al, 1996); cyclophosphamide 4000 mg m–2;
doxorubicin 70 mg m–2 every 3 weeks for 4 cycles (Shipp et al,
1995).
In other studies using additional blood cells with high-dose
chemotherapy (Basser et al, 1995; Stoppa et al, 1997; Viens et al,
1997) even if it is cumulative (Basser et al, 1995; Stoppa et al,
1997) thrombocytopenia seems to be less severe and the planned
dose intensity is easily respected (Basser et al, 1995; Viens et al,
1997). Overall, using peripheral blood stem cells seems to permit a
safer and more regular increase of dose intensity in high-dose
sequential chemotherapy regimens.
One of the risks in using peripheral blood stem cells is the mobi-
lization, collection and reinfusion of tumour cells (Brugger
et al, 1994). This is a potential risk in our study where most
patients had blood stem cell collection after the first cycle of
chemotherapy. However, the significance of circulating tumour
cells and impact of their potential reinfusion are not yet clearly
established, and ex vivo therapy is not considered presently as a
standard practice. So, it was decided in the context of such a multi-
centric study of first-line chemotherapy, to avoid purging and plan
secondary analysis of the possible impact of tumoural contamina-
tion on progression-free survival rather than on response, which
was the main objective of this study.
Among the 100 patients, one fatality was observed due to septic
shock during neutropenia. This death is clearly related to the
therapy, but overall, treatment-related mortality rate (»1%)
remains in the lower range of those reported in trials of high-dose
chemotherapy with stem cell transplantation.
Non-haematologic toxicities were essentially mucositis, occur-
ring more frequently after cycle 3 and 4 probably related to
administration of 5-FU.
Relative dose intensity was 0.97 (range 0.4–1.04) for
cyclophosphamide and 0.96 (range 0.25–1.05) for doxorubicin.
Eighty-seven patients received four cycles of chemotherapy, i.e.
15 g m–2 of cyclophosphamide, 300 mg m–2 of doxorubicin and
5000 mg m–2 of 5-FU in 9 weeks. This strategy of high-dose
sequential chemotherapy with stem cell support allows a total dose
of cyclophosphamide that is around 7.5 times higher than that
received in treatment which associates four cycles of standard
FAC (Feldman et al, 1986) and 3 times higher than in the FEC high
dose described by Chevallier et al (1995). Our data show that such
an increase in dose and dose intensity is accessible for 92% of
patients with non-metastatic inflammatory breast cancer with the
use of rG-CSF and peripheral stem cells.
The second end point of our study was to evaluate response
rate of inflammatory breast cancer to a dose-intensified cyclo-
phosphamide-doxorubicin 5-FU regimen. Clinical response rate
was high (OR: 90%), as generally described with other anthra-
cyclin-based regimens. When pathological response in breast was
considered in 87 evaluable patients, only 32% had total disappear-
ance of invasive tumoural cells. Several pathological response
rates, comparably defined, have been previously published after
conventional or moderately intensified systemic induction
chemotherapy (Table 5). Feldman et al (1986), using standard FAC
reported 12% of pathological complete response in breast among
90 patients. Chevallier et al (1995) using an intensified FEC
reported 22% of pathological complete response in 97 patients. In
other studies, where smaller numbers of patients were reported
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Table 5 Pathological response rate: comparison with conventional chemotherapy
Author Patient no. Chemotherapy Microscopic response
rate (%)
Feldman (Cancer Res, 1986) 90 5FU–D–Cy CR: 7
Israël (Cancer, 1986) 24 5FU–Cy CR: 0
‘Major response’: 17
Noguchi (Cancer, 1988) 28 MMC–5FU or D CR: 25
(Intra arterial)
Maloisel (Cancer, 1990) 44 D–5FU–Cy CR: 18
Armstrong 24 D–Cy- VC–MTX–L- CR: 17
(Breast Cancer Res Treat, 1993) 5FU
Chevallier (J Clin Oncol, 1995) 97 5FU–Ep–Cy CR: 22
± Lenograstim
Colozza (Am J Clin Oncol, 1996) 31 CDDP–D–Cy CR: 8
Present study 87 Cy-D-5FU CR: 32
High dose
D: doxorubicin, Cy: cyclophosphamide, MMC: mitomycin-c, VC: vincristine, 5-FU: 5-fluorouracil, MTX: methotrexate, L: leucovorin,
Ep: epirubicin, CDDP: cisplatin, CR: complete response.(inferior to 50), complete pathological response rate ranged from
0% to 18% after various combination chemotherapies (Israel et al,
1986; Maloisel et al, 1990; Armstrong et al, 1993; Colozza et al,
1996). Our results show a relatively higher pathological response
rate when compared to large series in the literature; however, it
remains limited, compared to the major increase in dose intensity
and total dose of chemotherapy, particularly of cyclophosphamide
(15 g m–2) which consequently resulted in an important increase in
toxicities and hospitalization. Is this because the main dose
increase was with cyclophosphamide? Recently, the NSABP
(Fisher et al, 1997) showed that a dose escalation of cyclophos-
phamide from 2400 mg m–2 to 4800 mg m–2 in 9 weeks did not
result in any benefit in the adjuvant situation. However, dose esca-
lation was much higher in our study, also IBC and adjuvant situa-
tion are different, consequently extrapolation of the NSABP
results to our study is difficult.
Chemotherapy regimen used in our study resulted essentially in
an increase of dose intensity with a relatively moderate increase in
dose, being the opposite of the general procedure in high-dose
chemotherapy with stem cell transplantation, which raises the
question of dose–effect versus dose–intensity. High pathological
response rate is generally reported with high-dose chemotherapy
with stem cell support in inflammatory breast cancer, but data are
available only for a very small number of studies and patients: two
pathological complete responses in two patients (Nieto et al,
1997), four pathological complete responses among nine patients
(Rosti et al, 1997), seven pathological complete responses in
18 mastectomies (Viens et al, 1998). Furthermore, most of these
patients were selected for response to standard chemotherapy prior
to intensification, which excludes analysis for poor responder
patients. Contrary to these studies, first-line high-dose sequential
chemotherapy, like ours, could be valuable in a large proportion of
patient, with untreated IBC. Similar encouraging results have been
reported with such a strategy in metastatic disease (Bezwoda et al,
1995) and in the adjuvant situation (Gianni et al, 1997) but using
generally higher dosages of alkylating agents. According to the
increase of pathological response rate, the 3-year survival is
encouraging, but the benefit cannot be definitely established on
that phase II study. More studies are needed to optimize the
chemotherapy sequence including other drugs, other escalation
and/or combinations.
Finally, the benefit of this approach needs to be prospectively
evaluated, in a randomized fashion against standard chemotherapy,
considering survival, cost and quality of life.
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